These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 16647758

  • 21. Iptakalim, a vascular ATP-sensitive potassium (KATP) channel opener, closes rat pancreatic beta-cell KATP channels and increases insulin release.
    Misaki N, Mao X, Lin YF, Suga S, Li GH, Liu Q, Chang Y, Wang H, Wakui M, Wu J.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):871-8. PubMed ID: 17522344
    [Abstract] [Full Text] [Related]

  • 22. Cardiac hERG K+ Channel as Safety and Pharmacological Target.
    Su S, Sun J, Wang Y, Xu Y.
    Handb Exp Pharmacol; 2021 Aug; 267():139-166. PubMed ID: 33829343
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
    Ridley JM, Milnes JT, Hancox JC, Witchel HJ.
    J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
    [Abstract] [Full Text] [Related]

  • 25. Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.
    Kim JG, Sung DJ, Kim HJ, Park SW, Won KJ, Kim B, Shin HC, Kim KS, Leem CH, Zhang YH, Cho H, Bae YM.
    PLoS One; 2016 Jan; 11(3):e0149198. PubMed ID: 26930604
    [Abstract] [Full Text] [Related]

  • 26. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K, Shimizu M, Ino H, Yamaguchi M, Terai H, Hoshi N, Higashida H, Terashima N, Uno Y, Kanaya H, Mabuchi H.
    Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S, Jensen GB, Sjøgren P, Korsgaard MP, Grunnet M.
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [Abstract] [Full Text] [Related]

  • 35. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
    Kang J, Chen XL, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D.
    Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.
    Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP.
    Prog Biophys Mol Biol; 2008 Mar; 98(2-3):137-48. PubMed ID: 19027781
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN.
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.